Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes drug showdown: which combo works best for obese patients?

NCT ID NCT07531108

Disease control Sponsor: Hawler Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested three different diabetes treatments in 186 overweight or obese adults newly diagnosed with type 2 diabetes. Participants received either empagliflozin plus metformin, sitagliptin plus metformin, or metformin alone for 12 weeks. Researchers measured changes in blood markers called omentin-1 and resistin, along with blood sugar and weight, to see which combination worked best.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Empagliflozin, Sitagliptin, and Metformin (oral diabetes drugs)
What this could lead to
If successful, this could help doctors choose the best initial drug combination for obese patients with type 2 diabetes, potentially improving blood sugar control and weight management.
What could go wrong
This is a small, completed Phase 4 study in one city in Iraq, so results may not apply to all populations. The main focus was on blood markers, not long-term health outcomes like heart disease or survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

186 people

The number who actually took part.

Started

Nov 2024

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 35 to 75 years. * Newly diagnosed treatment-naive type 2 diabetes mellitus with no comorbidities * HbA1c between 7% and 13%. * Overweight or obese status, with BMI 25 to 45 kg/m². * Waist circumference 94 to 130 cm for men or 80 to 130 cm for women. * Waist-to-height ratio between 0.50 and 0.90. * Willingness to provide written informed consent. Exclusion Criteria: * Clinically significant cardiovascular, renal, or hepatic disease. * Hypertension. * Pregnancy or breastfeeding. * Untreated or unstable thyroid disorders. * Active psychiatric illness or use of psychotropic medications. * Use of drugs known to affect adipokine levels, including glucocorticoids, statins, anti- inflammatory agents, hormonal therapies, or weight-loss medications. * Acute or ongoing infection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2

Contacts and locations

Locations

  • Galyawa Teaching Center for Diabetes and Endocrinology

    Erbil, 44001, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.